• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

World Conference on Lung Cancer(WCLC)

Jan 28 - 31, 2021

  1. AZD9150 cediranib (AZD2171)
  2. Ceralasertib (AZD6738) durvalumab
  3. Datopotamab deruxtecan (DS-1062)
  4. Durvalumab
  5. Durvalumab osimertinib
  6. Gefitinib
  7. Osimertinib
  8. Osimertinib gefitinib
  9. Osimertinib savolitinib
  10. Trastuzumab deruxtecan (T-DXd)

Pdf

HUDSON: an open-label, multi-drug, biomarker-directed, phase II platform study in patients with NSCLC, who progressed on anti-PD(L)1 therapy [OA07.08]

Pdf

Immuno-modulatory effects of ceralasertib in combination with durvalumab in NSCLC with progression on anti-PD(L)1 treatment (HUDSON) [P16.07]

Html

Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study [OA03.03]

Pdf

Interim analysis of neoadjuvant chemoradiotherapy and durvalumab for potentially resectable stage III non-small cell lung cancer (NSCLC) [FP03.02]

 

Pdf

Lung cancer symptoms at diagnosis: data from Thoracic Tumors Registry (TTR) [P52.05]

Pdf

Thoracic Tumors Registry (TTR): Analysis of clinical features and survival in patients with mNSCLC in Spain [P52.08]

Pdf

Profile of comorbidities and cancer history in patients with mNSCLC in the Spanish population, an interim analysis of the Thoracic Tumors Registry (RTT) [P52.10]

Pdf

Estimates of first-line extensive stage small cell lung cancer treatment rates from a U.S. claims database [P50.09]

Pdf

Population pharmacokinetics and exposure-response with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN [P48.21]

Pdf

Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A [OA01.04]

Pdf

First-line durvalumab plus platinum-etoposide in ES-SCLC: exploratory analyses based on extent of disease in CASPIAN [P48.03]

Pdf

An Observational Study of Treatment Outcome in Stage III Lung Cancer Patients in Taiwan: KINDLE study [P21.12]

Pdf

Real-world treatment patterns in Chinese Stage III NSCLC patients - a prospective, non-interventional study (MOOREA trial) [P21.10]

Pdf

Durvalumab in locally-advanced NSCLC in LATAM: Real world data from patients included in the early access program [P21.13]

Pdf

Durvalumab After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study [P17.02]

Pdf

MERMAID-1: A Phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery [P03.03]

Pdf

Patient characteristics and clinical outcomes of stage III NSCLC in a real-world setting: KINDLE Korean subset data [P04.03]

Pdf

The monitoring of mutated EGFR levels in liquid biopsy from patients on EGFR-TKIs – early detection of NSCLC progression [P35.05]

Pdf

Tissue- and plasma-based landscape of resistance to osimertinib [P76.18]

Pdf

A pan-Canadian validation study for the detection of EGFR-T790M mutations using circulating tumour DNA (ctDNA) from blood [FP07.08]

Pdf

A phase II study of osimertinib versus combination of osimertinib and chemotherapy for EGFR and T790M-mutation positive NSCLC [FP14.02]

Pdf

Post hoc analyses from an open label, multi-centre, ASTRIS trial of efficacy of osimertinib for CNS metastases with T790M-positive advanced NSCLC [FP14.14]

Html

A PET and MRI study exploring osimertinib brain exposure and efficacy in EGFRm NSCLC CNS metastases [P76.72]

Pdf

Osimertinib in poor PS patients with T790M-positive advanced NSCLC after progression of EGFR TKI treatments (NEJ032B) [P76.79]

Pdf

Osimertinib treatment in non-small cell lung cancer (NSCLC) EGFR-T790M+. Activity in patients with CNS metastases. OSIREX [P76.42]

Pdf

Real-world, first-line osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC [P76.66]

Html

ORCHARD: A biomarker-directed Phase 2 platform study in pts with advanced EGFRm NSCLC progressing on first-line osimertinib [P76.27]

Pdf

Real-world global data on targeting epidermal growth factor receptor in stage III non-small cell lung cancer: the results of the KINDLE study [P21.12]

Html

Patient-reported outcomes from ADAURA: osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC [OA06.03]

Html

Postoperative chemotherapy patterns and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR mutated NSCLC [OA06.04]

Pdf

Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer [P34.07]

Pdf

Retrospective epidemiological study of Locally Advanced Non-Small Cell Lung Cancer patients in Brazil – RELANCE (LACOG 0118) [P18.06]

Pdf

Phase 1 Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Patients with Advanced or Metastatic EGFR-Mutated NSCLC [P01.03]

Pdf

Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA [P03.02]

Pdf

Alternating osimertinib and gefitinib as second-line treatment for EGFR-mutated NSCLC harbouring a T790M resistance mutation (OSCILLATE) [P76.64]

Html

Osimertinib+savolitinib in pts with EGFRm MET-overexpressed/amplified NSCLC: Phase Ib TATTON Parts B/D final analysis [FP14.03]

Pdf

Trastuzumab deruxtecan plus pembrolizumab in advanced/metastatic breast or non-small cell lung cancer: A phase 1b study [P01.02]

Pdf

Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01 [OA04.05]

Pdf

Trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01 [MA11.03]

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice